Kinase Inhibitors Patent - VIDYA Therapeutics, Inc.

USPTO granted patent rights to VIDYA Therapeutics, Inc. for protein kinase inhibitors, specifically Bruton tyrosine kinase (BTK) inhibitors designed to penetrate the central nervous system. The patent covers pharmaceutical compositions, methods of preparing the inhibitors, and therapeutic uses for treating diseases associated with kinase function. The patent includes 21 claims.

Organizations engaged in kinase inhibitor research, drug development, or commercialization should evaluate freedom-to-operate to ensure their activities do not infringe the granted patent claims. Potential collaboration, licensing, or partnership opportunities with VIDYA Therapeutics may be relevant for parties seeking to develop BTK inhibitor therapies.